BioStock: Cereno Scientific raises 61 million SEK in warrant exercise

Cereno’s shareholders strongly believe in the company’s cardiovascular disease drug development portfolio. This much was clear at the end of Cereno’s latest TO2 series warrant exercise, which resulted in a subscription rate of well above 90 per cent, despite the turbulent investor climate we currently live in. The Swedish biotech raised just over 61 MSEK in the process, granting it further leeway to build upon its innovative treatment platform.

Read the article at biostock.se:

https://www.biostock.se/en/2022/10/cereno-scientific-tar-in-61-mkr-genom-nyttjande-av-teckningsoptioner/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/